GlassScriptPhysician profile
Lauren Moy
NPI 1275997942
$6,685.97
in general payments reported to CMS, 2019-2025
29 companies · $1,959 in 2025
The $1,959 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $971 · 2020: $48.92 · 2021: $203 · 2022: $808 · 2023: $1,055 · 2024: $1,641 · 2025: $1,959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,560 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,560.18 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,184.69 | 2022-2025 | Sotyktu |
| Organogenesis INC. | $873.78 | 2024-2025 | Cygnus Dual, Puraply Am, Via Matrix |
| Abbvie INC. | $703.13 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $485.11 | 2021-2025 | Ilumya, Winlevi, Blu-U |
| Galderma Laboratories, L.P. | $406.87 | 2021-2025 | Nemluvio |
| Merz North America, INC. | $390.48 | 2023-2024 | Xeomin |
| Regeneron Healthcare Solutions, INC. | $360.20 | 2019-2025 | Libtayo |
| Genzyme Corporation | $291.13 | 2019-2025 | |
| Janssen Biotech, INC. | $266.39 | 2022-2025 | Tremfya, Stelara, Simponi |
| Ucb, INC. | $213.61 | 2024-2025 | Bimzelx |
| Leo Pharma INC. | $157.07 | 2023-2025 | Adbry, Anzupgo |
| Smith+Nephew, INC. | $151.53 | 2022-2025 | Grafix Pl, Stravix, Oasis Micro |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $127.09 | 2019-2024 | Jublia, Cabtreo, Arazlo |
| Lilly USA, LLC | $113.27 | 2020-2025 | Ebglyss, Taltz, Zepbound |
| Strata Skin Sciences, INC. | $110.32 | 2024-2025 | Xtrac |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $106.96 | 2025 | |
| Mimedx Group, INC. | $101.91 | 2024-2025 | |
| Allergan, INC. | $97.33 | 2019 | |
| Almirall LLC | $95.23 | 2024-2025 | Klisyri, Seysara |
| Celgene Corporation | $91.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.42 | 2025 | |
| Revance Therapeutics, INC. | $78.20 | 2024 | Daxxify |
| Incyte Corporation | $51.12 | 2023-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $38.85 | 2024-2025 | Zoryve |
| Krystal Biotech INC | $26.11 | 2023 | Vyjuvek |
| Bioventus LLC | $25.93 | 2022 | |
| Stimlabs LLC | $23.99 | 2025 | Corplex P |
| Amgen INC. | $19.55 | 2024 | Otezla |
| Lnhc, INC | $14.70 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Moy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.